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Edited by Jesus AvilaAbstract Filamentous inclusions made of the microtubule-asso-
ciated protein tau in a hyperphosphorylated state are a deﬁning
feature of a large number of human neurodegenerative diseases.
Here we show that (trans,trans)-1-ﬂuoro-2,5-bis(3-hydroxycar-
bonyl-4-hydroxy)styrylbenzene (FSB), a ﬂuorescent Congo red
derivative, labels tau inclusions in tissue sections from a mouse
line transgenic for human P301S tau and in cases of familial
frontotemporal dementia and sporadic Picks disease. Labelling
by FSB required the presence of tau ﬁlaments. More impor-
tantly, tau inclusions in the spinal cord of human P301S tau
transgenic mice were labelled following a single intravenous
injection of FSB. These ﬁndings indicate that FSB can be used
to detect ﬁlamentous tau in vivo.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V.
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Open access under CC BY license.1. Introduction
The most common neurodegenerative diseases are character-
ized by the presence of abnormal ﬁlamentous protein inclu-
sions in nerve cells of the brain [1]. In Alzheimers disease
(AD), these inclusions are made of hyperphosphorylated tau
protein. Together with the extracellular b-amyloid deposits,
they constitute the deﬁning neuropathological characteristics
of AD [2]. Tau inclusions, in the absence of extracellular
deposits, are characteristic of progressive supranuclear palsy,
corticobasal degeneration, Picks disease, argyrophilic grain
disease and frontotemporal dementia and parkinsonism linked
to chromosome 17 (FTDP-17T) [3]. The identiﬁcation of
mutations in Tau in FTDP-17T has established that dysfunc-
tion of tau protein is central to the neurodegenerative process
[4–6].*Corresponding author. Fax: +44 1223 402197.
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deposits, such as b-amyloid and tau, precedes clinical symp-
toms, has led to attempts at developing reliable biomarkers
for neurodegenerative diseases. At present, work is most ad-
vanced for AD, where functional neuroimaging is showing
great promise for detecting pathological deposits, in particu-
lar b-amyloid, in asymptomatic patients and in patients in the
early stages of the disease [7,8]. A number of positron emis-
sion tomography tracer chemotypes is currently under inves-
tigation, including [18F]-FDDNP, [11C]-PIB, [11C]-SB13 and
[11C]-BF227 [9]. Most tracers are Congo red or thioﬂavin
derivatives, in keeping with the amyloid nature of the patho-
logical deposits [10,11]. These ligands, with the exception of
[18F]-FDDNP, display similar uptake in cerebral cortex of
AD patients, consistent with in vitro data showing that they
have a high aﬃnity for b-amyloid. [18F]-FDDNP also dis-
plays increased tracer uptake in the medial temporal lobe,
suggestive of a possible interaction with tau deposits [12].
Currently, only little is known about the ability of these
and related compounds to detect tau inclusions in brain. Previ-
ous work has shown that the Congo red derivative (trans,trans)-
1-bromo-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene
(BSB) can detect b-amyloid deposits in transgenic mouse brain
in vivo and in post mortem mouse and human brain [13]. This
compound has also been shown to detect tau inclusions in
tissue sections from human brain [14]. However, it failed to de-
tect inclusions in some tauopathies, including the neuronal
deposits in a case of FTDP-17T with the P301L mutation in
Tau. Subsequently, (trans,trans)-1-ﬂuoro-2,5-bis(3-hydroxycar-
bonyl-4-hydroxy)styrylbenzene (FSB), a ﬂuoro derivative of
BSB, was shown to be a more sensitive probe than BSB for
detecting b-amyloid deposits in tissue sections and in vivo
[15,16] and for detecting tau inclusions in AD brain [15].
Here we have used a previously described [17] transgenic
mouse model of human tauopathy and cases of human tau-
opathies to investigate the usefulness of FSB for detecting
tau inclusions. These mice express one isoform of human
four-repeat tau with the P301S mutation that causes FTDP-
17T [18], under the control of the murine Thy1 promoter.
They develop abundant deposits of ﬁlamentous tau through-
out the central nervous system (CNS), with the greatest load
in the spinal cord. We show labelling of ﬁlamentous tau by
FSB in post mortem tissue from mouse and human CNS
and in transgenic mouse spinal cord in vivo.by Elsevier B.V. Open access under CC BY license.
Fig. 1. Labelling of tau inclusions and b-amyloid deposits by FSB in transgenic mice. Spinal cord sections from 5 month-old mice transgenic for
human P301S tau and brain sections from 8 month-old mice transgenic for human amyloid precursor protein with mutations K670M/
N671L + V717F (line CRND8) were incubated with FSB at the indicated concentrations. Confocal microscopy was used to visualize the signal. Scale
bar, 150 lm.
902 A. Velasco et al. / FEBS Letters 582 (2008) 901–9062. Materials and methods
2.1. Animals and antibodies
Five month-old mice transgenic for human P301S tau [17], eight
month-oldmice transgenic for the 695 amino acid isoform of the human
amyloid precursor protein with mutations K670M/N671L + V717F
(line CRND8) [19] and age-matched C57BL/6J controls were used. We
made use of the phosphorylation-dependent anti-tau antibodies AT8
(Innogenetics, Ghent, Belgium) and AT100 (Innogenetics) and of the
phosphorylation-independent anti-tau antibodies BR134 [20] and T14
(Zymed, SanFrancisco, CA).All antibodieswere used at 1:500.AT8 rec-
ognizes tau protein phosphorylated at S202 and T205 [21], with AT100
requiring phosphorylation ofT212, S214 andT217 [22]. BR134 (directedFig. 2. FSB and anti-tau antibodies label the same structures in mice tran
transgenic mice were incubated with anti-tau antibodies BR134 (A), T14
sections were incubated with FSB. Confocal microscopy was used to visualiagainst the C-terminus of tau) recognizes murine and human tau iso-
forms irrespective of phosphorylation [20], whereas T14 is speciﬁc for
human tau (recognizing residues 141–149) [23].
2.2. Histochemistry and immunohistochemistry
Mice were perfused transcardially with 4% paraformaldehyde in
0.1 M phosphate buﬀer, pH 7.2. Brains and spinal cords were re-
moved, postﬁxed overnight and cryoprotected in 30% sucrose in
phosphate buﬀer for 24 h. Sagittal brain sections and transverse sec-
tions of the spinal cord (30 lm) were cut on a Leica SM2400 micro-
tome (Leica Microsystems, Bucks, UK) and stored at 4 C in
phosphate buﬀered saline (PBS) containing 0.1% sodium azide. Sec-
tions were permeabilized and blocked for 3 h at room temperaturesgenic for human P301S tau. Spinal cord sections from 5 month-old
(B), AT100 (C) and AT8 (D). Following immunohistochemistry, the
ze the signal. Scale bar, 60 lm.
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Fig. 3. FSB labels ﬁlamentous tau: (A) Recombinant human P301S tau protein was incubated in the absence (No ﬁlaments) or the presence
(ﬁlaments) of heparin and labelled with FSB. Intrinsic ﬂuorescence was then measured. Scale bar, 300 nm. (B) Spinal cord sections from 5 month-old
human P301S tau mice were incubated with 90% formic acid. Following immunohistochemistry with anti-tau antibody AT8, the sections were
incubated with FSB. Scale bar, 60 lm.
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For staining with FSB (Dojindo Laboratories, Kumamoto, Japan),
sections were incubated for 30 min in blocking solution. For immu-
nohistochemistry, sections were incubated overnight at 4 C with
the primary antibodies in blocking solution. After washing the sec-
tions were incubated for 3 h at room temperature in Cy3 (Stratech
Scientiﬁc, Newmarket, UK) secondary antibodies in blocking solu-
tion. Paraﬃn-embedded sections (10 lm) of formalin-ﬁxed brain tis-
sue from the frontal cortex of a case of FTDP-17T with the P301L
mutation in Tau [24] and a case of sporadic Picks disease were also
used. The sections were deparaﬃnized and rehydrated. Antigen re-
trieval was performed by incubating the sections in 10 mM sodium
citrate buﬀer, pH 6.0, for 15 min in a microwave oven. Endogenous
peroxidase activity was quenched during a 90 min incubation in 20%
methanol/3% hydrogen peroxide. Following permeabilization and
blocking in Tris-buﬀered saline-0.2% Tween containing 5% goat ser-
um, the sections were incubated overnight at 4 C with the primary
antibodies in blocking solution. After washing, the sections were
incubated for 2 h at room temperature with the Alexa Fluor 568 sec-
ondary antibody (Molecular Probes). Following washing, the signalwas revealed with the tyramide signal ampliﬁcation kit. Sections were
mounted using Vectashield (Vector Laboratories, Burlingame, CA)
and viewed through a Biorad Radiance 2000 confocal microscope
(Biorad, Hertford, UK).
2.3. Binding of FSB to synthetic tau ﬁlaments
Expression and puriﬁcation of human P301S tau protein was done
as described [25]. Puriﬁed recombinant protein (3 mg/ml) was incu-
bated in the presence or absence of heparin (400 lg/ml; Sigma–Aldrich,
Suﬀolk, UK) in 25 ll of 30 mM MOPS, 1 mM 4-(2-aminoethyl)ben-
zenesulphonylﬂuoride (AEBSF, Calbiochem), pH 7.4, at 37 C for
72 h, as described [26]. Aliquots were placed onto carbon-coated
400-mesh grids and stained with 1% lithium phosphotungstate. Micro-
graphs were recorded at a nominal magniﬁcation of X40,000 on a Phi-
lips model EM208S electron microscope. Intrinsic ﬂuorescence was
measured using 0.75 ll tau ﬁlament assembly mixture and 0.63 lM
FSB in 10 mM sodium phosphate, 1 mM EDTA, pH 7.4, supple-
mented with 10% ethanol. After 1 h, intrinsic ﬂuorescence was mea-
sured in a Ultra Evolution 384 plate reader (Tecan, Reading, UK)
using a 340–440 nm ﬁlter pair.
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Human P301S tau mice were injected intravenously with 300 ll of
0.1% FSB (2.4 mM) in PBS containing 2% mouse albumin. After var-
ious times, the mice were perfused transcardially with 4% paraformal-
dehyde in 0.1 M phosphate buﬀer, pH 7.2. Spinal cords were removed,
postﬁxed overnight and cryoprotected for 24 h. Transverse sections
(20 lm) were cut using a Leica CM3050S cryostat (Leica Microsys-
tems) and analysed by confocal microscopy.3. Results
3.1. Detection of ﬁlamentous tau inclusions by FSB in a mouse
model of human tauopathy
Spinal cord sections from 5 month-old mice transgenic for
human P301S tau with numerous ﬁlamentous tau inclusions
were incubated with FSB at concentrations ranging from 0.1
to 100 lM. Strong ﬂuorescence was observed when FSB was
used at 10 and 100 lM, with weak labelling at 0.1 and 1 lM
(Fig. 1). Previous work has shown that FSB can detect b-amy-
loid deposits in transgenic mouse brain [16]. We have con-
ﬁrmed these ﬁndings using brain sections from mouse line
CRND8, where FSB visualized plaques when used at 0.1, 1,
10 and 100 lM. To investigate whether FSB was staining tau
inclusions in the spinal cord of transgenic human P301S tau
mice, we performed double labelling with anti-tau antibodies
and FSB. As shown in Fig. 2, FSB labelled the same cells with
tau inclusions as anti-tau antibodies BR134, T14, AT100 and
AT8. At higher magniﬁcation, FSB and AT8 labelled tau
inclusions to the same extent (Fig. 2D). To investigate whether
aggregation of tau was required for the binding of FSB, we
used assembled and non-assembled recombinant human
P301S tau protein (Fig. 3A). The measurement of intrinsic
ﬂuorescence showed binding of FSB to ﬁlamentous, but not
monomeric, tau. This was conﬁrmed using spinal cord sectionsFig. 4. FSB and anti-tau antibody AT8 label the same structures in human t
the P301L mutation in Tau. (B) Frontal cortex section from a case of spora
incubated with FSB. Scale bars, 60 lm.from human P301S tau mice treated with 90% formic acid. The
latter is known to disassemble ﬁlamentous inclusions [27]. Pre-
treatment with formic acid for 1–15 min gradually eliminated
the staining of tau inclusions by FSB. By contrast, staining
with the phosphorylation-dependent anti-tau antibody AT8
remained unchanged.
3.2. Detection of ﬁlamentous tau inclusions by FSB in human
tauopathies
Frontal cortex sections from a case of FTDP-17 T with the
P301L mutation in Tau and a case of sporadic Picks disease
were used. Immunohistochemistry for phosphorylated tau
was followed by incubation with FSB. As shown in Fig. 4,
tau-positive structures were labelled by FSB in both FTDP-
17T and Picks disease.
3.3. Detection of ﬁlamentous tau inclusions following the
intravenous injection of FSB in transgenic mice
To investigate whether FSB could be used to detect tau
inclusions in vivo, we injected 5 month-old human P301S trans-
genic mice intravenously with 300 ll of 0.1% FSB (2.4 mM).
The mice were killed at various times after the injection, with
at least 3 mice per time point. As shown in Fig. 5, numerous
nerve cells in spinal cord were labelled 4 h after the injection,
with weaker labelling at 2 h. Immunohistochemistry using
anti-tau antibody AT8 showed that FSB labelled tau-immuno-
reactive nerve cells (Fig. 5D).4. Discussion
We have used a mouse line transgenic for human P301S
tau protein [17] that exhibits the essential features of humanauopathies. (A) Frontal cortex section from a case of FTDP-17T with
dic Picks disease. Following immunohistochemistry, the sections were
Fig. 5. FSB labels ﬁlamentous tau inclusions in vivo. Five month-old human P301S tau transgenic mice received a single intravenous injection of
0.1% FSB. One hour (A), 2 h (B) and 4 h (C) after the injection the mice were perfused, the spinal cord sectioned and analysed by confocal
microscopy. Scale bar, 150 lm. (D), Motor neurons labelled following the intravenous injection of FSB were also immunoreactive with anti-tau
antibody AT8. Scale bar, 60 lm.
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FSB for detecting ﬁlamentous tau inclusions. In tissue sections
of spinal cord from 5 month-old transgenic mice, FSB readily
detected tau inclusions when used at a concentration in excess
of 10 lM. Previously, the related compound BSB was used to
detect tau inclusions in brain sections from human tauopathies
[13,14]. We also detected tau inclusions in brain and spinal
cord sections from human P301S tau transgenic mice using
BSB, but found it to be less sensitive at detecting inclusions
than FSB (data not shown). BSB and FSB also detected amy-
loid plaques in the brain of transgenic CRND8 mice, in agree-
ment with previous results [13,14,16]. Their ability to detect
plaques was greater than that to detect tau inclusions. It re-
mains to be seen whether this is due to a higher intrinsic bind-
ing aﬃnity for plaques or whether the extracellular location of
plaques and their larger size also play a role.
In tissue sections from transgenic mice, FSB labelled the
same structures as phosphorylation-dependent anti-tau anti-
bodies. However, unlike these antibodies, it only recognized
tau protein in a ﬁlamentous state. In the mouse line transgenic
for human P301S tau protein, ﬁlamentous inclusions are made
predominantly of a single four-repeat human tau isoform [17].
This contrasts with cases of FTDP-17T caused by the P301L
mutation in Tau, where the three four-repeat tau isoforms
make up the inclusions [24] and with sporadic Picks disease,
where the three tau isoforms with three repeats each makeup the ﬁlaments [28]. In frontal cortex from a case with the
P301L mutation in Tau and a case of Picks disease, FSB la-
belled tau inclusions, indicating that it binds to all human
brain tau isoforms in a ﬁlamentous state. When compared to
a previous study reporting only weak labelling of Pick bodies
by BSB and no labelling of neuronal inclusions in a case with
the P301L mutation in Tau [14], the present ﬁndings show con-
clusively that FSB is a more sensitive probe for detecting tau
ﬁlaments than BSB.
The ability to identify tau inclusions in vivo is essential for
experimental studies in animals and for diagnostic purposes
in humans [29,30]. We found that FSB can readily label tau
inclusions in transgenic mice following a single intravenous
injection, demonstrating that it can be used for the live imag-
ing of tau pathology. Like Congo red, FSB has previously been
shown to inhibit the heparin-induced ﬁlament formation of tau
in vitro [31]. It remains to be seen whether the repeated admin-
istration of FSB can reduce the formation of ﬁlamentous tau
inclusions in brain and spinal cord of mice transgenic for
human P301S tau.
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